{"name":"MCM Vaccines B.V.","slug":"mcm-vaccines-b-v","ticker":"","exchange":"","domain":"","description":"MCM Vaccines B.V. is a specialized biopharmaceutical company focused on the development and commercialization of innovative vaccines. The company has a robust pipeline with five key products, including four in Phase 3 trials and one marketed vaccine, Pediacel®.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Hib-MCC","genericName":"Hib-MCC","slug":"hib-mcc","indication":"Prevention of invasive Haemophilus influenzae type b disease","status":"phase_3"},{"name":"MCC-CRM","genericName":"MCC-CRM","slug":"mcc-crm","indication":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C","status":"phase_3"},{"name":"MCC-TT","genericName":"MCC-TT","slug":"mcc-tt","indication":"Prevention of meningococcal disease and tetanus","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PR5I","genericName":"PR5I","slug":"pr5i","indication":"Prevention of pneumococcal disease","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Pediacel®","genericName":"Pediacel®","slug":"pediacel","indication":"Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children","status":"marketed"}]}],"pipeline":[{"name":"PR5I","genericName":"PR5I","slug":"pr5i","phase":"phase_3","mechanism":"PR5I is a therapeutic vaccine designed to stimulate immune responses against pneumococcal serotypes to prevent pneumococcal disease.","indications":["Prevention of pneumococcal disease"],"catalyst":""},{"name":"Pediacel®","genericName":"Pediacel®","slug":"pediacel","phase":"marketed","mechanism":"Pediacel is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.","indications":["Active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children"],"catalyst":""},{"name":"Hib-MCC","genericName":"Hib-MCC","slug":"hib-mcc","phase":"phase_3","mechanism":"Hib-MCC is a conjugate vaccine that combines Haemophilus influenzae type b (Hib) polysaccharide with meningococcal C conjugate to stimulate immune protection against both pathogens.","indications":["Prevention of invasive Haemophilus influenzae type b disease","Prevention of invasive meningococcal C disease"],"catalyst":""},{"name":"MCC-CRM","genericName":"MCC-CRM","slug":"mcc-crm","phase":"phase_3","mechanism":"MCC-CRM is a meningococcal C conjugate vaccine that stimulates immune responses against Neisseria meningitidis serogroup C through conjugation of the polysaccharide capsule to a carrier protein.","indications":["Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C"],"catalyst":""},{"name":"MCC-TT","genericName":"MCC-TT","slug":"mcc-tt","phase":"phase_3","mechanism":"MCC-TT is a therapeutic vaccine designed to stimulate immune responses against meningococcal and tetanus pathogens through conjugate technology.","indications":["Prevention of meningococcal disease and tetanus"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":4,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}